Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 8,353 Shares of Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Shannon Devers sold 8,353 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $75.95, for a total transaction of $634,410.35. Following the transaction, the executive vice president owned 26,518 shares of the company’s stock, valued at approximately $2,014,042.10. This represents a 23.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Ionis Pharmaceuticals Stock Up 1.6%

NASDAQ:IONS opened at $77.53 on Wednesday. Ionis Pharmaceuticals, Inc. has a twelve month low of $23.95 and a twelve month high of $86.15. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. The stock’s 50 day moving average price is $78.90 and its two-hundred day moving average price is $64.33. The firm has a market capitalization of $12.56 billion, a price-to-earnings ratio of -45.88 and a beta of 0.28.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.35. The firm had revenue of $156.72 million for the quarter, compared to analyst estimates of $131.75 million. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 44.26%. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.95) earnings per share. Equities research analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current fiscal year.

Key Stories Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Analyst / media bullishness on olezarsen: A recent Seeking Alpha piece highlights an expected 2026 launch of olezarsen in SHTG and argues that approval/commercial rollout could drive a substantial revenue inflection for Ionis; the article notes strong recent momentum and positions olezarsen as the key upside catalyst. Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
• Neutral Sentiment: Trading and technicals: Intraday volume is elevated (~4.9M shares vs. a ~1.5M average), suggesting the market is actively reacting to the news flow; the stock is above its 200‑day moving average (support) but near the 50‑day average—momentum could depend on upcoming clinical/commercial milestones.
• Negative Sentiment: Large, concentrated insider selling: Multiple executives (including CEO Brett P. Monia and several EVPs) sold shares on Jan 16 totaling roughly 117K shares (~$8.8M) — CEO sale (~44K shares, ~$3.3M) and several EVP sales of ~8–13K shares each. These filings can be reviewed in the SEC disclosures, which may signal tax/diversification activity but can also weigh on sentiment.
  Bennett filing
  Birchler filing
  Devers filing
  Hougen filing
  Jenne filing
  Kordasiewicz filing
  Monia (CEO) filing
  O’neil filing
  Schneider filing
  Swayze filings

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. CWM LLC raised its stake in shares of Ionis Pharmaceuticals by 7.3% during the third quarter. CWM LLC now owns 2,488 shares of the company’s stock valued at $163,000 after acquiring an additional 170 shares during the last quarter. Wedmont Private Capital increased its holdings in Ionis Pharmaceuticals by 3.2% during the 4th quarter. Wedmont Private Capital now owns 5,536 shares of the company’s stock valued at $460,000 after purchasing an additional 173 shares during the period. Golden State Wealth Management LLC raised its position in Ionis Pharmaceuticals by 198.4% during the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after purchasing an additional 250 shares during the last quarter. Public Employees Retirement System of Ohio lifted its holdings in Ionis Pharmaceuticals by 0.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 48,545 shares of the company’s stock worth $3,176,000 after buying an additional 301 shares during the period. Finally, Steigerwald Gordon & Koch Inc. bought a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth approximately $25,000. 93.86% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Needham & Company LLC increased their price target on shares of Ionis Pharmaceuticals from $78.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Piper Sandler raised their target price on shares of Ionis Pharmaceuticals from $70.00 to $77.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. Barclays boosted their price target on Ionis Pharmaceuticals from $80.00 to $95.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. JPMorgan Chase & Co. raised shares of Ionis Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $49.00 to $80.00 in a research note on Wednesday, October 8th. Finally, Guggenheim lifted their price target on Ionis Pharmaceuticals from $90.00 to $92.00 and gave the company a “buy” rating in a research note on Tuesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $87.05.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.